{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:45:47Z","timestamp":1773283547735,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100006197","name":"Fonden til L\u00e6gevidenskabens Fremme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Relapse constitutes the greatest threat to event\u2010free survival after completion of treatment for childhood acute lymphoblastic leukaemia (ALL). However, evidence on optimal follow\u2010up schedules is limited. The aims of the present population\u2010based cohort study were to assess the value of current follow\u2010up schedules after completion of Nordic Society of Paediatric Haematology and Oncology ALL protocol treatment and to estimate the impact of relapse detection mode on overall survival (OS). Among 3262 patients diagnosed between 1992 and 2014 and who completed treatment, 338 developed a relapse. Relapse detection was equally distributed between extra visits (50\u00b78%) and scheduled follow\u2010up visits (49\u00b72%). All cases detected at an extra visit and 64\u00b73% of cases detected at a scheduled visit presented with symptoms or objective findings. Neither the mode of detection {adjusted hazard ratio 0\u00b795, [95% confidence interval (CI) 0\u00b761\u20131\u00b748] for scheduled visits} nor the duration of symptoms was an independent risk factor for OS after relapse. The estimated number of scheduled blood samples needed to diagnose one subclinical relapse during the first 5\u00a0years after treatment cessation was 1269 (95% CI 902\u20131637). In conclusion, based on OS data, scheduled visits after cessation of therapy seem to yield no extra benefit. These results should frame future follow\u2010up strategies.<\/jats:p>","DOI":"10.1111\/bjh.17555","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T07:24:13Z","timestamp":1622100253000},"page":"734-744","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Detection mode of childhood acute lymphoblastic leukaemia relapse and its effect on survival: a Nordic population\u2010based cohort study"],"prefix":"10.1111","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0811-8818","authenticated-orcid":false,"given":"Karen S.","family":"Jensen","sequence":"first","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine Aarhus University Hospital Aarhus Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trausti","family":"Oskarsson","sequence":"additional","affiliation":[{"name":"Department of Paediatric Oncology Karolinska University Hospital Stockholm Sweden"},{"name":"Childhood Cancer Research Unit Department of Women\u00b4s and Children\u00b4s Health Karolinska Institutet Stockholm Sweden"},{"name":"Children\u2019s Hospital Landspitali University Hospital Reykjavik Iceland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e4ivi M.","family":"L\u00e4hteenm\u00e4ki","sequence":"additional","affiliation":[{"name":"Department of Paediatric and Adolescent Haematology\/Oncology Turku University Hospital FICAN\u2010West Turku University Turku Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trond","family":"Flaegstad","sequence":"additional","affiliation":[{"name":"Department of Paediatrics University of Troms\u00f8 and University Hospital of North Norway Troms\u00f8 Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kjeld","family":"Schmiegelow","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine Copenhagen University Hospital Copenhagen Denmark"},{"name":"Institute of Clinical Medicine Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Vedsted","sequence":"additional","affiliation":[{"name":"Research Unit for General Practice Department of Public Health Aarhus University Aarhus Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgitte K.","family":"Albertsen","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine Aarhus University Hospital Aarhus Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Schr\u00f8der","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine Aarhus University Hospital Aarhus Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Nordic Society of Paediatric Haematology and Oncology (NOPHO)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,5,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djg064"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.251"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.265"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.131680"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.48.6522"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.11.1207"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20370"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04453.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20166"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20356"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"e_1_2_8_15_1","unstructured":"vonStackelbergA QiC SahaV LocatelliF MoschandreasJ LoveS.IntReALL SR 2010: an international randomised phase III study for the treatment of standard risk childhood relapsed acute lymphoblastic leukaemia (abstract). NCRI Cancer Conference; November 5\u20138 2017; Glasgow. Available at:https:\/\/abstracts.ncri.org.uk\/abstract\/intreall\u2010sr\u20102010\u2010an\u2010international\u2010randomised\u2010phase\u2010iii\u2010study\u2010for\u2010the\u2010treatment\u2010of\u2010standard\u2010risk\u2010childhood\u2010relapsed\u2010acute\u2010lymphoblastic\u2010leukaemia\/. Accessed May 2021."},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.1983"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.251"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(95)00048-8"},{"key":"e_1_2_8_19_1","first-page":"A4883","article-title":"Bone marrow involvement is not manifest in the early stages of childhood acute lymphoblastic leukaemia","volume":"61","author":"Brix N","year":"2014","journal-title":"Danish Med J"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-11-20"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cdp.2008.06.001"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30293-6"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000000591"},{"key":"e_1_2_8_24_1","unstructured":"WilsonJM JungnerG;World Health Organization.Principles and practice of screening for disease.1968. Available at:https:\/\/apps.who.int\/iris\/handle\/10665\/37650."}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17555","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.17555","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T17:35:31Z","timestamp":1692812131000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.17555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,27]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1111\/bjh.17555"],"URL":"https:\/\/doi.org\/10.1111\/bjh.17555","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,27]]},"assertion":[{"value":"2021-01-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}